BioAdaptives

BioAdaptives EV/Revenue

The EV/Revenue (Enterprise Value to Revenue) of BioAdaptives (BDPT) as of Oct 25, 2026 is 20.25. In the previous year, EV/Revenue (Enterprise Value to Revenue) was 27.61 — a change of -26.65% (lower).

EV/Revenue

20.25

YoY

-26.65%

Last updated:

EV/Revenue (Enterprise Value to Revenue) of BioAdaptives is 2025 20.25 . EV/Revenue (Enterprise Value to Revenue) of BioAdaptives was 2024 27.61 . It decreases by -26.65% lower compared to the previous year.

The BioAdaptives EV/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/Revenue
Date
EV/Revenue
Jan 1, 2016
6.97 USD
Jan 1, 2019
50.45 USD
Jan 1, 2020
38.10 USD
Jan 1, 2021
25.17 USD
Jan 1, 2022
29.73 USD
Jan 1, 2023
14.44 USD
Jan 1, 2024
27.61 USD
Jan 1, 2025
20.25 USD
The BioAdaptives EV/Revenue history
YEAREV/RevenueYoY
20.25-26.65%
27.61+91.16%
14.44-51.43%
29.73+18.12%
25.17-33.93%
38.10-24.48%
50.45+623.30%
6.97—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioAdaptives Stock analysis

What does BioAdaptives do? BioAdaptives, Inc. generates revenue through the sale of health and wellness products including dietary supplements, specialty food items, and devices that optimize bioelectromagnetic availability. The company markets PrimiCell and PrimiLive under a product agreement with Ferris Holding, Inc., targeting consumers seeking cognitive enhancement, fatigue reduction, and anti-aging solutions. PrimiTrim serves the weight control segment, while Equine Regen and Equine Regen Plus are in advanced testing for veterinary use. The firm also develops a dog product, expanding its wellness offerings across human and animal health markets. Ferris Holding, Inc. provides the intellectual property and products that BioAdaptives markets, including PrimiCell and PrimiLive, which are positioned for cognition, focus, and emotional wellness. The company's advanced-stage products Equine Regen and Equine Regen Plus cater to the veterinary segment, with PrimiTrim addressing weight management needs. BioAdaptives' product portfolio spans nutraceuticals, devices, and specialty foods designed to improve physical and emotional wellness across multiple consumer segments. BioAdaptives focuses on selling devices and nutraceuticals that target cognitive performance, fatigue reduction, and anti-aging, with PrimiCell and PrimiLive as key products under the Ferris agreement. The company's weight control solution PrimiTrim appeals to consumers seeking wellness through diet, while Equine Regen and Equine Regen Plus target animal health providers. The firm's development of a dog product further diversifies its offerings in the wellness market. BioAdaptives is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioAdaptives stock

EV/Revenue (Enterprise Value to Revenue) of BioAdaptives is 20.25 in 2025.

EV/Revenue (Enterprise Value to Revenue) of BioAdaptives changed from 27.61 to 20.25, representing a -26.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/Revenue (Enterprise Value to Revenue) BioAdaptives since 2006 – with annual values, charts, and detailed analysis.

The EV/Revenue ratio compares a company's enterprise value to its total revenue. It is particularly useful for valuing high-growth companies that may not yet be profitable.

To evaluate EV/Revenue (Enterprise Value to Revenue)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/Revenue (Enterprise Value to Revenue).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/Revenue (Enterprise Value to Revenue)'s BioAdaptives with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — BioAdaptives

All Key Metrics — BioAdaptives